Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
eXoZymes (NASDAQ:EXOZ), a pioneer in AI-engineered enzymes for sustainable biomanufacturing, announced key leadership appointments to BioMADE Governance Committees. CCO Damien Perriman has been elected to the BioMADE Leadership Council, while VP of Development Dr. Paul Opgenorth joins the Technical Committee.
These appointments position eXoZymes as a thought leader in cell-free biomanufacturing, with both executives set to influence national priorities and technical roadmaps through BioMADE, a federally funded Manufacturing Innovation Institute. Dr. Opgenorth brings additional expertise from his role as PI in the NSF's CFIRE program and BioMADE 4.0 project.
eXoZymes (NASDAQ:EXOZ), pioniere degli enzimi progettati con IA per una bioproduzione sostenibile, ha annunciato importanti nomine nei comitati di governance di BioMADE. CCO Damien Perriman è stato eletto nel BioMADE Leadership Council, mentre VP dello Sviluppo Dr. Paul Opgenorth entra nel Technical Committee.
Queste nomine posizionano eXoZymes come leader di pensiero nella bioproduzione cell-free, con entrambi gli executive pronti a influenzare priorità nazionali e roadmaps tecnici tramite BioMADE, un Istituto federale dedicato all'Innovazione nella produzione. Il Dr. Opgenorth porta ulteriori competenze dal suo ruolo di PI nel programma CFIRE della NSF e nel progetto BioMADE 4.0.
eXoZymes (NASDAQ:EXOZ), pionero en enzimas diseñadas con IA para una bioproducción sostenible, anunció nombramientos clave en los comités de gobernanza de BioMADE. CCO Damien Perriman fue elegido para el BioMADE Leadership Council, mientras que VP de Desarrollo Dr. Paul Opgenorth se incorpora al Technical Committee.
Estos nombramientos posicionan a eXoZymes como líder de pensamiento en bioproducción sin células, con ambos ejecutivos listos para influir en prioridades nacionales y hojas de ruta técnicas a través de BioMADE, un Instituto de Innovación en Manufactura financiado por el gobierno. El Dr. Opgenorth aporta experiencia adicional desde su rol como PI en el programa CFIRE de la NSF y el proyecto BioMADE 4.0.
eXoZymes (NASDAQ:EXOZ), 지속 가능한 바이오제조를 위한 AI로 설계된 효소의 선구자, BioMADE 거버넌스 위원회에서의 주요 리더십 임명을 발표했습니다. CCO Damien Perriman가 BioMADE Leadership Council에 선출되었고, 개발 부사장 Dr. Paul Opgenorth가 Technical Committee에 합류합니다.
이 임명은 셀프-프리 바이오제조에서 eXoZymes를 사상 리더로 포지셔닝하며, 두 경영진은 BioMADE를 통해 연방 자금 지원 제조 혁신 연구소의 역할에 따라 국가 우선순위와 기술 로드맵에 영향을 미칠 예정입니다. Dr. Opgenorth는 NSF의 CFIRE 프로그램과 BioMADE 4.0 프로젝트의 PI로서의 역할에서 추가 전문 지식을 제공합니다.
eXoZymes (NASDAQ:EXOZ), pionnier des enzymes conçues par IA pour une bioproduction durable, a annoncé des nominations clés au sein des comités de gouvernance de BioMADE. CCO Damien Perriman a été élu au BioMADE Leadership Council, tandis que VP du Développement Dr. Paul Opgenorth rejoint le Technical Committee.
Ces nominations positionnent eXoZymes comme un leader d'opinion dans la bioproduction sans cellules, les deux dirigeants devant influencer les priorités nationales et les roadmaps techniques via BioMADE, un institut fédéral financé pour l'Innovation en Manufacturing. Le Dr Opgenorth apporte une expertise supplémentaire en tant que PI dans le programme CFIRE de la NSF et dans le projet BioMADE 4.0.
eXoZymes (NASDAQ:EXOZ), Pionier bei KI-entwickelten Enzymen für eine nachhaltige Bioproduktion, gab wichtige Führungsberufungen in den Governance-Ausschüssen von BioMADE bekannt. CCO Damien Perriman wurde in den BioMADE Leadership Council gewählt, während VP of Development Dr. Paul Opgenorth dem Technical Committee beitritt.
Diese Ernennungen positionieren eXoZymes als Vordenker der zellfreien Bioproduktion, wobei beide Führungskräfte nationale Prioritäten und technische Roadmaps durch BioMADE beeinflussen sollen, ein Bundesinstitut für Fertigungsinnovation. Dr. Opgenorth bringt zusätzliche Expertise aus seiner Rolle als PI im NSF CFIRE-Programm und dem BioMADE 4.0-Projekt ein.
eXoZymes (NASDAQ:EXOZ)، الرائد في الإنزيمات المصممة بالذكاء الاصطناعي من أجل تصنيع بيولوجي مستدام، أعلن عن تعيينات قيادية رئيسية في لجان الحوكمة التابعة لـ BioMADE. CCO Damien Perriman انتُخب في مجلس قيادة BioMADE، بينما انضم نائب الرئيس للتطوير الدكتور بول أبغنورث إلى اللجنة الفنية.
هذه التعيينات تضع eXoZymes كقائد فكر في Bioproduction الخالية من الخلايا، مع استعداد التنفيذيين للمساهمة في تشكيل الأولويات الوطنية وخطط الطريق الفنية من خلال BioMADE، المعInstitute الوطني الممول اتحاديًا للابتكار في التصنيع. يجلب الدكتور أبغنورث خبرة إضافية من دوره كباحث رئيسي في برنامج CFIRE التابع NSF ومشروع BioMADE 4.0.
eXoZymes (NASDAQ:EXOZ)，在可持续生物制造领域通过 AI 设计的酶的先驱，宣布在 BioMADE 治理委员会中的关键领导任命。CCO Damien Perriman 当选进入 BioMADE Leadership Council，而 开发副总裁 Dr. Paul Opgenorth 加入 Technical Committee。
这些任命使 eXoZymes 成为无细胞生物制造领域的思想领袖，两位高管将通过 BioMADE 这一联邦资助的制造创新研究院，影响国家优先事项和技术路线图。Opgenorth 博士还将结合他在 NSF CFIRE 计划及 BioMADE 4.0 项目中的 PI 经验，带来额外的专业知识。
- Strategic appointments to influential BioMADE committees strengthen company's industry position
- Leadership roles enable direct influence on national biomanufacturing priorities and funding strategies
- Access to cross-pollination opportunities through NSF and BioMADE 4.0 projects
- None.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that two of its senior leaders - CCO Damien Perriman and VP of Development, Dr. Paul Opgenorth - have been elected to key roles within the BioMADE Governance Committees.
Chief Commercial Officer at eXoZymes, Damien Perriman, states, "Being elected to the BioMADE Leadership Council is both an honor and a responsibility. This is a pivotal moment where cell-free biomanufacturing is stepping into the national spotlight. At eXoZymes, we believe our technology will be instrumental in driving the shift toward faster, more scalable, and more resilient biomanufacturing. I look forward to working with fellow council members to shape priorities that unlock real-world impact across industries - from fuels to functional ingredients."
Co-founder and VP of Development, Dr. Paul Opgenorth, states, "The Technical Committee is where the details of innovation become the standards that move an industry forward. I'm excited to play a role in defining a technical roadmap for developing and deploying cell-free enzyme pathways in the real world that can accelerate biosolution development cycles, remove the cell-based bottlenecks, and make a new generation of highly valuable natural product molecules commercially viable at scale."
These appointments underscore eXoZymes' commitment to - and growing influence as a thought leader in - cell-free biomanufacturing. BioMADE, the federally funded Manufacturing Innovation Institute for bioindustrial manufacturing, plays a pivotal role in shaping national priorities, funding strategies, and technology roadmaps. By securing representation on both the Leadership Council and Technical Committee, eXoZymes is helping set the agenda for how cell-free technologies will scale across industries.
Dr. Paul Opgenorth, continues, "Our work at eXoZymes has demonstrated how cell-free enzyme systems can achieve exceptional purity, speed, and scalability compared to traditional approaches. By contributing insights from this work - coupled with cross-pollinating knowledge and ideas from my role as a PI in the National Science Foundation (NSF) multi-million dollar "Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications" (CFIRE) program as well as our BioMADE 4.0 project - I aspire to help ensure that the United States of America becomes the global leader in cell-free biomanufacturing."
About BioMADE
By supporting the development of biomanufacturing technologies, BioMADE and its network of nearly 350 members across 40 states are strengthening American competitiveness, creating a more resilient supply chain, reshoring manufacturing jobs, and producing biobased products without relying on foreign inputs. BioMADE is also building a globally competitive STEM workforce to ensure American workers are prepared and ready to fill new jobs within this rapidly growing industry. BioMADE was catalyzed by the U.S. Department of Defense (DoD) in October of 2020 and is a proud member of Manufacturing USA®. More info available here: https://www.biomade.org
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
SOURCE: eXoZymes
View the original press release on ACCESS Newswire
FAQ
What positions did eXoZymes executives secure at BioMADE in September 2025?
What is eXoZymes' (NASDAQ:EXOZ) main technology focus?
What is BioMADE's role in the biomanufacturing industry?
What additional projects is Dr. Paul Opgenorth involved in besides his role at eXoZymes?
